Chemists once cooked up new ring systems with little idea about their future applications. 7-Chloro-1,2,3,4-Tetrahydrobenzo[B]azepin-5-one emerged from such curiosity. Early records show research in the late 20th century focusing on azepine derivatives and their skeletons due to their potential in pharmaceuticals. Initially overlooked for simpler amides and lactams, tetrahydrobenzoazepines gained respect after strong activity in CNS-modulating compounds. Many pharmaceutical patents filed in the 1980s mention azepinones as central structures, not always starring as the active ingredient but often as the key intermediates turning simple aromatic rings into potent seven-membered scaffolds. Laboratories in Europe and the US quietly refined scalable protocols, and by the turn of the century, bulk orders for this chemical ticked upward when medicinal chemists began pursuing structures that could slip past known resistance mechanisms in CNS targets.
7-Chloro-1,2,3,4-Tetrahydrobenzo[B]azepin-5-one looks dry and technical on paper, but this white-to-off-white solid holds more than meets the eye. On the synthetic chemist's bench, it acts as a versatile building block, leading research efforts into new treatments for neurological disorders. Its backbone supports modifications that allow chemists to tweak properties for improved bioactivity and stability. Anybody who has handled its bottle knows this compound’s clean features make purification straightforward, which speeds up method development and reduces frustrations common with stickier, more finicky heterocyclic compounds.
A typical batch of the compound presents as a crystalline powder with a melting point generally between 140 and 150°C, signaling high purity. Solubility shows a strong preference for organic solvents, especially DMSO and chloroform, giving researchers flexibility when designing protocols. The chlorine atom at position 7 influences reactivity, opening the door for nucleophilic aromatic substitution, which has proved especially handy for custom analog synthesis. Infrared spectra display the characteristic lactam carbonyl stretch right in the 1700 cm-1 region. Its stability stands out: stored properly, the material resists degradation and hydrolysis, supporting long-term experimental work. This is key for labs looking to keep reference samples on hand over several project cycles.
In any catalogue, buyers expect specifics: purity at least 98%, LC/MS-verified, with single digits for moisture and residual solvents. Proper labeling—lot number, expiry date, full name, and hazard pictograms—makes traceability and compliance straightforward. For logistics, suppliers pack this solid in amber glass with desiccant, helping avoid light and moisture effects. Standard packs range from 1 gram for research up to 100 grams for pilot work. Transparency in the supply chain has become more important as regulators push for tighter quality controls on precursors feeding into CNS drug studies.
Most synthetic pathways begin with a substituted aniline—either 2-chloroaniline or a related precursor. Ring closure through cyclization happens after acylation and reduction, and the process runs in polar aprotic solvents with mild heating. Catalysts like palladium complexes or copper salts often step in for certain bond-forming reactions. Hydrogenation under pressure takes care of aromatic saturation while keeping the lactam ring intact. Crystallization from ethanol or isopropanol usually suffices for purification, sparing researchers the pain of fine-tuning column chromatography for every batch. Waste streams contain mostly benign byproducts, but the reaction calls for good ventilation and containment, given the volatility of some amine starting materials.
The chlorine in the seven position helps structure-activity relationship studies. Chemists can swap it for amines, ethers, thiols, and even fluorine with careful conditions, multiplying options for biological testing. The nucleophilic sites on the ring’s nitrogen allow straightforward N-alkylation, and the lactam carbonyl stands ready for reductions to amines or conversions to imides. In medicinal chemistry campaigns, the core often wears a morpholine or piperidine ring for solubility improvements. Simple hydrogenation brings more flexibility to the core by offering routes to saturated azepines. Derivatives adapted with bulky groups around the azepine backbone have become increasingly common in patent literature, especially for novel CNS ligands and antipsychotic leads.
Over the years, suppliers and researchers have catalogued this chemical under names such as 7-Chloro-5-oxo-1,2,3,4-tetrahydrobenzo[b]azepine and 7-Chloro-5H-benzo[b]azepin-5-one. Often, abbreviated forms like CTBA or simply “chloroazepinone” sneak into shipping documentation, but regulatory filings rely on IUPAC or CAS-registered titles. In some pharmacological studies, experimental compounds list this as a “core scaffold,” a testament to its central role even if it rarely appears in a final drug structure’s generic name.
Workers dealing with 7-chloro-1,2,3,4-tetrahydrobenzo[B]azepin-5-one should follow strict chemical hygiene practices. Typical material safety data points out skin and eye irritancy, with gloves and goggles listed as standard PPE. Fume hoods help handle dust or solvent dispersions. Most suppliers offer certificates confirming tests for trace metal and class 1 solvent levels given the compound’s use in preclinical work. In my lab experience, smallest spills clean easily, and routine risk assessment found no evidence of unusual sensitization or volatility. Waste must not enter the regular drain, given the possibility of persistent intermediates forming downstream, so designated hazardous waste collection stays mandatory. Regulatory compliance now includes regular auditing of purchase, storage, and disposal records — a step up from the loose handling of earlier decades.
Mainstream application stays in medicinal chemistry, especially as a starting point for synthesizing CNS-active molecules. Drug discovery programs use this core to build libraries for screening against dopamine receptor subtypes and other GPCR targets. Some groups explore it for kinase inhibitor programs where unique ring geometry exposes previously untouchable binding pockets. Veterinary research sometimes uses azepinone derivatives in antiparasitic screens. The general adaptability of the seven-membered scaffold attracts structure-based drug design and fragment-based screening campaigns. As more data accumulates on brain permeability and metabolic stability, biotechs keep expanding scope far beyond the original neuroactive paradigms.
The steady pace of discovery with benzoazepinones owes a lot to how amenable they prove to late-stage functionalization. Medicinal chemists routinely map out SAR campaigns, making minor tweaks on the core to alter activity and selectivity. High-throughput screening methods paired with parallel synthesis allow dozens, sometimes hundreds, of analogs in a season. Crystallographic studies and in silico docking feed insights back into the analogue design loop. I’ve seen computational chemists favor this class in CNS-focused machine learning models because the backbone supplies rich data, and moves in property space correlate with measurable changes in animal models. Collaborations blossom between academia and industry, since new targets often demand access to rare or modified azepinones that specialty suppliers hesitate to produce at scale. Open-access databases now track not only the molecules, but synthesis protocols and anecdotal lab notes, speeding up each new iteration.
Existing safety data do not point to acute risks in low-dose laboratory handling, but full toxicity profiles remain mostly unpublished. Preclinical animal studies report low oral and dermal toxicity, but the compound hasn't reached the chronic exposure evaluations typical for marketed drugs. In screening runs, researchers monitor for hepatic and renal markers, and no consistent red flags come up, yet most protocols treat the material as hazardous due to incomplete long-term data. Mutagenicity and carcinogenicity assays continue at contract research labs to support regulatory filings for new analogs. Environmental toxicity remains unquantified, so waste controls err on the side of caution. Institutions share unpublished safety data through informal networks, which helps keep best practices evolving with new findings.
Demand for bespoke CNS-active scaffolds keeps rising as standard targets become saturated by existing chemotypes. With benzoazepinones, chemists can chase new pharmacological space by extending or modifying the core, addressing not just resistance but also solubility, metabolic vulnerability, and bioavailability. AI-driven retrosynthetic planning opens up routes to azepinones never tried before, making laboratory synthesis less of a bottleneck. The next decade points to even smaller and smarter libraries built off this structural unit, feeding next-generation machine learning models for hit identification. As regulatory oversight expands, full documentation and validated toxicity data will shape who can access and use this compound family, tightening supply chains but improving reproducibility and safety. For experienced hands, the compound’s blend of versatility, relative simplicity, and proven utility promises it will stay a fixture on laboratory shelves, evolving alongside the science it supports.
7-Chloro-1,2,3,4-tetrahydrobenzo[b]azepin-5-one is not splashed across headlines or plastered on big banners in the world of pharmaceutical chemistry, but it gets a quiet nod in research labs. This compound lands squarely in the middle of drug discovery and development, especially for psychiatric and neurological drugs. It crops up as a valuable intermediate. Intermediates act as stepping stones in complex syntheses. Without these building blocks, chemists have to invent trickier methods or spend more time getting to the target molecule.
Medicinal chemistry never quite stops searching for better treatments for problems like depression, anxiety, and epilepsy. Benzazepines—the family connected to this compound—spark interest since they share some biological features with drugs like L-DOPA or certain muscle relaxants. The chlorine atom at the seventh position brings an edge, giving it properties that could influence receptor binding and biological activity. That sort of chemical modification matters a lot; subtle tweaks change how well a drug works or what sorts of side effects pop up.
Several papers in the past decade mention derivatives from this backbone as candidates for research into antipsychotic or anticonvulsant medications. It’s the sort of detail you don’t notice in your medicine chest at home, but chemists notice right away. They know this scaffold can be stitched into more complex medicines, and the presence of chlorine can open doors to pharmacological profiles that plain variants don’t reach.
For anyone who wonders if these intermediate compounds actually have impact, take the story of clozapine and similar drugs for schizophrenia. Modified azepines stand behind the scenes, acting like lighthouses for researchers hunting the next breakthrough. Without core pieces like 7-chloro-1,2,3,4-tetrahydrobenzo[b]azepin-5-one, there’s a lot less to build on. Researchers can try to leap from raw starter materials directly to complex medicines, but success rates drop and costs climb. That means patients waiting on a new therapy end up waiting longer.
The pharmaceutical industry can sometimes draw suspicion when it tries new molecules. Safety must come first. Detailed toxicology studies run on intermediates as well as final products. Regulations worldwide keep an eye on these research chemicals to make sure they go only to labs following strict safety and reporting rules.
Supply chain transparency forms another issue often missed in technical discussions. Intermediates usually get passed along several chemical companies before anyone uses them in a real-world setting. Tracing each step matters for safety, environmental impact, and ethical manufacturing. Some companies step ahead by using green chemistry techniques, reducing waste or avoiding toxic reagents in making this compound. Every improvement upstream helps shrink the environmental bill for a single tablet of finished medicine.
The drive to create new psychiatric or neurological medications never feels done. Compounds like 7-chloro-1,2,3,4-tetrahydrobenzo[b]azepin-5-one could unlock progress for diseases that still don’t get enough attention. With the right oversight, ethical sourcing, and investment in clean chemistry, there’s a path to better and safer drugs.
Years of working in pharmaceutical science taught me that chemical names often look intimidating but usually describe clear, logical structures. 7-Chloro-1,2,3,4-Tetrahydrobenzo[B]azepin-5-one carries a name that hints at its makeup if we break it down. The core is a benzoazepine: seven carbons, fused with a benzene ring, and interrupted by a nitrogen atom in the azepine ring. "Tetrahydro" tells us that four hydrogen atoms saturate the ring, making the backbone less aromatic. A chlorine atom on the seventh carbon and a ketone (one) group at position five complete the puzzle. This leads us to the formula: C11H10ClNO.
Clear, robust understanding of chemical formulas matters, whether you’re in a lab, a classroom, or just reading a medication label. I’ve seen mistakes emerge from a single wrong letter in a formula: deliveries go wrong, synthesis steps get botched, or regulatory reports lose accuracy. The formula C11H10ClNO isn’t just a dry bookshelf fact; it represents a scaffold upon which complex functions and potential therapies rest. In industry, knowing exactly what’s in a compound helps screen for toxicity and anticipate metabolic pathways. This level of detail helps industry workers avoid hazards and gives medical professionals a precise map for understanding drug behavior in the body.
Ask anyone who’s slogged through drug development: even one atom can change everything. A missing hydrogen can transform a harmless molecule into a toxin. In the case of 7-chloro-1,2,3,4-tetrahydrobenzo[b]azepin-5-one, the presence of both chlorine and a ketone creates potential for new interactions with enzymes. Chlorinated rings often show up in drugs and agricultural chemicals because chlorine tweaks how the body breaks down the compound. The ketone makes it a good candidate for further chemical modifications, which research chemists eagerly exploit to create derivatives.
I’ve watched dry-lab discussions get heated when someone glosses over how subtle changes to a molecule’s formula can open it up to abuse or cause unexpected side effects. Precision keeps dangerous errors at bay. The regulatory side steps in here: agencies need to see unambiguous, atomic-level detail to approve safe use. Leaving out elements or misplacing a chlorine could lead to batch failures or even expensive recalls.
Getting students, researchers, or even curious readers to pay attention to these formulas builds a safer, more competent scientific community. I believe that fostering deeper interest in chemical literacy sidesteps a lot of future mistakes. Infographics, digital molecule models, and hands-on labs do a great job anchoring these abstract details into tangible skills. Each person who internalizes how to read molecular formulas can catch an error before it spirals into a critical mistake.
A future with fewer chemical mishaps depends not just on better equipment but on growing a culture where precision in molecular formulas is the rule. Giving people solid training, backing it up with strong digital reference tools, and keeping oversight sharp prevents errors that put real lives at risk. Every time a chemist writes C11H10ClNO and double-checks it, they’re upholding a commitment to clear, accurate, and meaningful science.
Some chemicals have a habit of changing character if left on a warm windowsill or stored next to cleaning supplies. I learned this the blunt way in a college lab—the cleaner the storage practice, the fewer headaches later. With research compounds like 7-Chloro-1,2,3,4-Tetrahydrobenzo[B]Azepin-5-One, the stakes go beyond inconvenience. Sloppy storage can invite strange odors, lost potency, waste of grant money, and even safety risks.
This compound falls into the benzoazepine group, showing some sensitivity to heat and light. Leaving bottles out basically turns the experiment into a coin toss. I’ve seen labels fade, powders clump, and solutions turn yellow—all signs that the chemistry has changed and any experiment depending on precise mass or reactivity isn’t finishing well.
A lot of labs I’ve worked in keep sensitive samples in a locked, climate-controlled cabinet. Cool temperatures slow down any chemical reactions that could zap the material before it gets used. A temperature range just above freezing and under 8°C extends the shelf life. I’ve found that keeping samples in the fridge just above the family yogurt means fewer surprises down the road, provided spills get cleaned fast.
Moisture messes with many organic substances. Lingering water vapor creeps in through unsealed lids and triggers hydrolysis, changing the composition and inviting mold. A container with a strong, screw-on top and a packet of silica gel handles humidity. Sealing isn’t just a formality—pouring the powder back and forth between containers or opening the bottle every day for a “quick check” can shorten its lifespan.
UV rays represent an invisible hazard. Some compounds literally split or rearrange when left soaking in sunlight. Once, an undergraduate left a vial on a window ledge and the pale-white powder turned orange over the weekend. For any benzoazepine, avoid see-through glass unless the cabinet is dark and solid. Choosing amber bottles for storage blocks most light and keeps changes at bay. Chemicals with a yellow or brown hue do best shielded from direct and even indirect light.
Every container should carry a clear label—with the chemical name, date received, and hazard codes. This habit kept my old lab running without confusion and let anyone checking the shelf spot old or expired material. If an accidental spill happens, quick action starts with knowing what you’re dealing with, including potential respiratory risks. Several sources—including Sigma-Aldrich and PubChem—stress personal protective equipment and a ventilated hood or cabinet.
No matter how short the storage, double-bagging and using secondary containers guard against spills. Documenting each batch’s origin and date—whether on paper or digitally—saves countless hours chasing mysterious degradation. Unopened chemical drums last longer, but real life in lab work means bottles get opened and closed. Air and moisture sneak in, so minimizing each exposure to the environment preserves both purity and people’s time.
Bringing these habits to the workplace trains the team and protects results. Mistakes because of degraded chemicals affect people’s reputations, budgets, and even safety when toxic byproducts form. Treating every new reagent with the care you would give to milk in summer heat pays off at every step from receiving to disposal.
Not everyone spends their morning thinking about the availability of 7-Chloro-1,2,3,4-Tetrahydrobenzo[B]Azepin-5-One. For those in pharmaceutical R&D or chemical manufacturing, though, that question isn’t so rare. There’s a growing trend for specialty synthesis ingredients and building blocks like this, especially as mid-sized labs and new companies hunt for shortcuts on their way to developing new molecules. Planning out a synthesis pipeline can stall at this step: if a lab can’t lock in a steady supply of a starting ingredient, the brakes stay on the project. Running into a “no stock” message isn’t just frustrating; it can mean tens of thousands of dollars lost on project stalls or contract delays.
Tracking down 7-Chloro-1,2,3,4-Tetrahydrobenzo[B]Azepin-5-One, I discovered that most catalogs put it into the “contact us for availability” zone. This old trick means suppliers probably make it to order, not off the shelf. In the chemical industry, that usually signals low demand, complex synthesis routes, or heavy regulation—sometimes all three. Bulk requests push up against a catch-22: manufacturers don’t keep large stocks on hand without buyers, and buyers put off major purchases unless stock is sure to be available.
Larger international suppliers sometimes list this compound, promising multi-kilogram deliveries, but lead times can stretch up to several months. That’s a lifetime in an industry where deadlines really matter. Cold reality: only the biggest players have enough negotiating power to force short lead times or get firm guarantees.
Medicinal chemists chase after structures like this for two big reasons: new treatments for neurological disorders and specialty research tools. Some promising drug candidates use this molecule as a skeleton for more complex targets. Chemists like me know that a limited supply or sudden out-of-stock status can leave you with only half of your project running, while you waste days scrambling for a new vendor or shifting synthetic plans.
Rarely, local suppliers try custom synthesis, but costs jump fast, making bulk orders less affordable unless you’re lining up a major contract. No wonder so many stick with routine, off-the-shelf tools—if you gamble on a rare compound, the clock and the accountant both start breathing down your neck.
Solving these supply headaches takes some creativity. More transparency from suppliers about their real-time inventory would help project managers decide early if they should scout for alternatives or try an in-house synthesis route. Buyers could band together through purchasing consortiums, creating enough demand for a manufacturer to keep larger batches on hand, lowering costs for everyone.
Policy changes could help, too. Encouraging regional manufacturing reduces shipping delays and cuts through red tape from cross-border drug precursor regulations. Investing in faster route optimization technology makes it easier for custom synthesis outfits to ramp up production without months of trial and error.
People with hands-on lab experience know that nothing slows a project like waiting for a bottle to show up. Whether you’re scaling up a pharmaceutical process or charting a new path in drug discovery, certainty about access to raw materials like 7-Chloro-1,2,3,4-Tetrahydrobenzo[B]Azepin-5-One makes a world of difference. The industry could use less mystery and more reliability, and everyone benefits when those shelves aren’t standing empty.
I’ve worked for years alongside chemical compounds, some of which sound like tongue twisters and pack a punch. 7-Chloro-1,2,3,4-tetrahydrobenzo[B]azepin-5-one fits that description. It’s a specialty intermediate, and like a lot of similar substances, it doesn’t offer second chances if handled carelessly. The sheer challenge lies in not just recognizing danger, but respecting its unpredictability.
Once you read the safety data sheet for anything in this family, a few things jump right out. This stuff can irritate skin, eyes, and may cause respiratory issues if inhaled. I’ve seen what a splash can do in a fume hood—rashes, watery eyes, coughing fits. So, nobody in their right mind walks into a lab without proper gloves, a buttoned lab coat, and snug safety goggles. Nitrile gloves give you more chemical resistance than latex, and long sleeves keep your forearms protected. Never underestimate the need for a sturdy pair of shoes—there’s enough risk already without adding exposed toes to the mix.
A key lesson learned from long days in the lab: open benches create hazards that tend to catch you off-guard. Fume hoods turn a reckless experiment into a controlled process. Even with a nose for trouble, I can’t smell every vapor, and it only takes a low concentration of fumes to prompt a headache or worse. Running all procedures under a ventilated hood offers a real layer of protection, not just against accidental inhalation but against longer-term exposure risks scientists now know too well.
Wiping up chemical spills isn’t like cleaning up coffee. A colleague once tried using paper towels on a minor spill; he ended up with irritated skin for days. Instead, absorbent pads meant for chemical cleanup and a well-rehearsed spill protocol keep incidents from escalating. Containing and neutralizing spills beats improvisation every single time. Skin contact still happens, so copious washing with water—right away—helps limit the aftermath. I make it a habit to walk new team members through emergency showers and eyewash stations before the day begins.
It’s tempting to tuck chemical bottles out of the way, but improper storage can turn a quiet room into a ticking bomb. 7-Chloro-1,2,3,4-tetrahydrobenzo[B]azepin-5-one stays stable in a cool, dry locker. I keep it tightly sealed, labeled clearly, away from oxidizers and sources of ignition. Flammable cabinets and explosion-proof refrigerators serve a real purpose. If a shelf looks overloaded, bottles perched precariously, it’s time to reorganize. Shortcuts almost always backfire.
Following written procedures and disposal routes protects not only the individual, but the environment and everyone down the line. I’ve seen coworkers cut corners, only to double back when waste started to build up. Disposal through certified waste channels, and never down a sink, keeps local water sources safe. Double-checking label accuracy and expiry dates before each use helps avoid surprises, especially since chemical integrity fades over time.
No amount of caution can replace hands-on training and a team that takes responsibility seriously. Sharing experiences, swapping stories about close calls, and reminding each other about forgotten steps keep safety culture alive. In my years under the fluorescent lights, trust between team members and respect for every safety rule have kept accidents rare. Real safety grows from habits, not hope, and those habits shape the peace of mind that lets you focus on the science, not the risk.
| Names | |
| Preferred IUPAC name | 7-chloro-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-one |
| Other names |
7-Chloro-2,3,4,5-tetrahydro-1-benzazepin-5-one 7-Chloro-5-oxo-2,3,4,5-tetrahydro-1-benzazepine 7-Chlorotetrahydro-1-benzazepin-5-one |
| Pronunciation | /ˈklɔːr.oʊ ˈtɛtrəˌhaɪdroʊ ˈbɛnzoʊ ˈæzəpɪn ˈfaɪv oʊn/ |
| Identifiers | |
| CAS Number | 105674-68-4 |
| 3D model (JSmol) | `3Dmol.js('CC1=CC(=O)NC2=CC=CC=C12')` |
| Beilstein Reference | 89642 |
| ChEBI | CHEBI:191557 |
| ChEMBL | CHEMBL2103881 |
| ChemSpider | 22659695 |
| DrugBank | DB07867 |
| ECHA InfoCard | 13-1-2841149752-57-0000 |
| EC Number | NA |
| Gmelin Reference | Gmelin 83378 |
| KEGG | C11041 |
| MeSH | D017382 |
| PubChem CID | 1366448 |
| RTECS number | GN8240000 |
| UNII | RXG6Q8RW47 |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C9H10ClNO |
| Molar mass | 211.67 g/mol |
| Appearance | White to off-white solid |
| Odor | Odorless |
| Density | 1.31 g/cm3 |
| Solubility in water | Slightly soluble in water |
| log P | 2.07 |
| Acidity (pKa) | 15.05 |
| Basicity (pKb) | 2.99 |
| Magnetic susceptibility (χ) | -57.10·10^-6 cm^3/mol |
| Refractive index (nD) | 1.648 |
| Viscosity | Viscous oil |
| Dipole moment | 3.5884 |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 218.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -21.5 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | –4241 kJ·mol⁻¹ |
| Pharmacology | |
| ATC code | N05CF03 |
| Hazards | |
| Main hazards | Causes skin irritation. Causes serious eye irritation. May cause respiratory irritation. |
| GHS labelling | GHS02,GHS07 |
| Pictograms | GHS07 |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | P264, P270, P280, P301+P312, P305+P351+P338, P337+P313 |
| NFPA 704 (fire diamond) | 1-2-0 |
| Flash point | Flash point: >110 °C |
| NIOSH | RN101146-97-0 |
| PEL (Permissible) | PEL (Permissible exposure limit) information for 7-Chloro-1,2,3,4-Tetrahydrobenzo[B]Azepin-5-One is not specifically established by OSHA or ACGIH. |
| REL (Recommended) | REL: 10 mg/m3 |
| Related compounds | |
| Related compounds |
7-Chloro-1,2,3,4-tetrahydrobenzo[b]azepine 1,2,3,4-Tetrahydrobenzo[b]azepin-5-one 7-Chloro-5H-benzo[b]azepin-5-one 1,2,3,4-Tetrahydro-7-chlorobenzazepin-5-one |